Allogene Therapeutics has reported data from the planned interim futility analysis of its pivotal, randomised phase-II ALPHA3 trial in first-line (1L) consolidation Large B-Cell Lymphoma (LBCL).

At the protocol-defined data cutoff, which was triggered when the 24th patient completed day 45 MRD assessment, 58.3 percent (7/12) of patients in the cemacabtagene ansegedleucel (cema-cel) arm achieved Minimal Residual Disease (MRD) negativity compared to 16.7 percent (2/12) in the observation arm. This represents a 41.6 percent absolute difference in MRD clearance between the two arms. Based on literature, a difference in percentage points of 25-30 percent in the MRD clearance could translate into meaningful clinical benefit at study completion. In addition, at the first MRD assessment (day 45), plasma ctDNA levels decreased from baseline by a median of 97.7 percent in the cema-cel arm compared to a 26.6 percent median increase in the observation arm. The company believes these interim data provide initial support for cema-cel’s potential as a novel strategy for treating high-risk patients at the end of first-line treatment.

“Early MRD clearance in this setting is encouraging and supports the potential for cema-cel to change how we approach high-risk LBCL at the end of first-line therapy,” said Zachary Roberts, MD, PhD, EVP, Research and Development and Chief Medical Officer, Allogene. “These interim data suggest that an off-the-shelf CAR T may be able to intervene during that important window before clinical relapse to eliminate residual disease and make earlier intervention feasible in routine clinical practice. We look forward to the next study milestones as the trial continues to further define the potential of cema-cel.”

MRD status post-treatment has emerged as a strong predictor of relapse in LBCL, creating a potential opportunity to intervene earlier in the course of disease, when disease burden is low, but the risk of progression remains high. The ALPHA3 trial is the first randomised study in LBCL designed to assess whether MRD-guided intervention before relapse can eliminate residual disease and potentially prevent recurrence. The study identifies high-risk patients using Natera’s CLARITY MRD assay which is powered by its phased variant MRD technology. Patients with LBCL who have completed curative-intent treatment in both front-line and later line settings, including autologous CAR T therapy, and who achieve MRD negative status by technology have demonstrated improved Progression-Free Survival (PFS) and EFS compared to those who do not attain MRD-negative status.

“Our goal has always been to move CAR T from a bespoke procedure available at a limited number of centres to a scalable therapy that can reach patients more broadly,” said David Chang, MD, PhD, President, Chief Executive Officer and Co-Founder, Allogene. “Although still early, the ALPHA3 results show encouraging MRD clearance and a favourable safety profile. Combined with the advantages of an off-the-shelf CAR T platform—rapid availability, operational simplicity, and potential for outpatient use—cema-cel, if approved, could leapfrog existing options and enable earlier intervention in the disease course.”